Related Experiment Videos
Corticosteroid-Induced osteoporosis: detection and management
1Department of Medicine, St Joseph's Hospital, McMaster University, Hamilton, Ontario, Canada. jd.adachi@sympatico.ca
Drug Safety
|August 2, 2001
Summary
Corticosteroid-induced osteoporosis is a significant health issue. Bisphosphonates are recommended for preventing bone loss and fractures in patients on long-term corticosteroid therapy.
Area of Science:
- Endocrinology
- Bone Biology
- Pharmacology
Background:
- Corticosteroid-induced osteoporosis is a leading cause of secondary osteoporosis and associated morbidity.
- Preventative treatments are often underutilized in patients receiving corticosteroid therapy.
- Osteoblast apoptosis induced by corticosteroids contributes significantly to bone loss.
Purpose of the Study:
- To review the role of osteoblasts in corticosteroid-induced osteoporosis.
- To evaluate the efficacy of various therapeutic agents in preventing corticosteroid-induced bone loss.
- To highlight bisphosphonates as the leading evidence-based therapy.
Main Methods:
- Review of recent research on osteoblast apoptosis.
- Analysis of large-scale randomized controlled trials for therapeutic agents.
- Comparison of bone mineral density and fracture rates across different treatments.
Main Results:
- Bisphosphonates demonstrate the strongest evidence for preventing corticosteroid-induced bone loss.
- Significant increases in bone mineral density at the spine and hip were observed with bisphosphonates.
- Clinically significant reductions in vertebral fracture rates were noted, particularly in postmenopausal women.
Conclusions:
- Bisphosphonates are the most supported therapy for corticosteroid-induced osteoporosis.
- Patients requiring corticosteroids for over 3 months should be offered preventative treatment.
- Further evidence is needed for other therapies regarding hip bone mass and fracture reduction.